艾伯维21亿美元再加码：体内CAR-T是下一个竞争高地？

Core Insights - AbbVie announced a cash acquisition of Capstan Therapeutics for up to $2.1 billion, gaining a potential first-in-class tLNP anti-CD19 CAR-T therapy candidate and Capstan's proprietary tLNP platform technology [2] - Capstan Therapeutics focuses on developing in vivo CAR-T therapies using LNP-mRNA technology, having raised nearly $100 million in Series A funding led by Pfizer Ventures [2] - The in vivo CAR-T field is gaining traction, with significant research advancements and increasing interest from multinational pharmaceutical companies [2][3] Industry Overview - Since the first CAR-T product approval in 2017, seven CAR-T therapies have been approved by the FDA, with projected global sales exceeding $4.5 billion by 2024 [3] - Traditional CAR-T therapies face challenges such as complex manufacturing processes, high costs, and severe side effects, limiting their widespread application [3][4] - Innovations in CAR-T therapy are focusing on three main paths: universal CAR-T (UCAR-T), dual-target/logic-gate CAR-T, and in vivo CAR-T, which simplifies the manufacturing process and reduces costs [4] Technological Developments - In vivo CAR-T therapies can significantly lower costs and reduce hospital stays by generating T cells directly in the patient's body [4] - The two main technological routes for in vivo CAR-T are lentiviral vectors and RNA delivery systems, each with distinct advantages and challenges [4][5] - The in vivo CAR-T technology has high barriers to entry, with only a few companies currently involved, highlighting the competitive landscape [5] Capital and Strategic Moves - AbbVie is actively seeking growth opportunities in the in vivo CAR-T space, having previously entered a $1.4 billion agreement with Umoja Biopharma for CAR-T cell therapy development [6] - Other pharmaceutical companies, including Astellas and AstraZeneca, are also making significant investments in in vivo CAR-T technologies through partnerships and acquisitions [7][8] - Chinese biotech firms are emerging in the in vivo CAR-T arena, with companies like YunTing and Origin Bio collaborating on next-generation therapies [8]